deCODE genetics of Iceland says that, using its proprietary dataminingproducts, its scientists have to date discovered 350 genes in key drug target classes, including G protein-coupled receptors, kinases, proteases, ion channels, nuclear receptors and transglutamenases.
Also, using the deCODE Clinical Genome Miner, it has placed these genes in the context of population linkage data in over 40 common diseases. It has applied for patents on the targets identified and has included the relevant disease-linkage data in its applications.
deCODE will integrate these targets into its growing in-house drug discovery program. The ability to correlate these targets with a wide range of specific disease data adds to the value of drug development, as well as the strength of the firm's intellectual property position, it notes. It plans to continue to use the Clinical Genome Miner to generate new proprietary knowledge about the connections between genes and disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze